Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Positive anti-HBc tied to cirrhosis, HCC in NAFLD patients

Stephen Padilla
25 Jun 2020
Hepatitis B is still widely prevalent worldwide despite effective vaccination programmes in many countries.

A recent study involving Chinese patients with nonalcoholic fatty liver disease (NAFLD) suggests that positive antihepatitis B core antibody (anti-HBc) is linked to cirrhosis and possibly hepatocellular carcinoma (HCC) and cirrhotic complications.

“In this large cohort of patients with biopsy-proven NAFLD, we show that positive anti-HBc was associated with cirrhosis independent of age and metabolic factors,” the researchers said. “Patients with positive anti-HBc also had a higher incidence of liver-related events.”

Overall, 489 patients with biopsy-proven NAFLD and 69 with NAFLD-related or cryptogenic HCC were included in this multicentre study. Anti-HBc was used to detect the previous hepatitis B virus (HBV) infection.

Positive anti-HBc correlated with lower steatosis grade but higher fibrosis stage in the biopsy cohort. Of the patients, 18.8 percent with positive and 7.5 percent with negative anti-HBc had cirrhosis, respectively (p<0.001). The significant association between anti-HBc and cirrhosis persisted even after adjusting for age and metabolic factors (adjusted odds ratio, 2.232, 95 percent confidence interval, 1.202–4.147). [Am J Gastroenterol 2020;115:867-875]

Furthermore, positive anti-HBc was associated with a higher incidence of HCC or cirrhotic complications (6.5 percent vs 2.2 percent; p=0.039) over a mean follow-up of 6.2 years. In addition, positive anti-HBc was present in 73.9 percent of patients with NAFLD-related or cryptogenic HCC. On the other hand, no association was found between antihepatitis B surface antibody and histological severity.

Several studies have also reported an association between positive anti-HBc and HCC in patients with chronic hepatitis C. [Gastroenterology 2004;126:102-110; J Hepatol 2013;59:696-700; J Clin Microbiol 2002;40:4068-4071; Hepatology 2011;54:434-442; Intervirology 2008;51:352-361; Scand J Gastroenterol 2008;43:849-856]

“Although all of our patients had negative serum HBV DNA, a few reasons may explain the association between anti-HBc positivity and HCC,” the researchers said.

“First, in all chronic liver diseases, the clinical outcome is determined not only by the current but also past disease activity. Patients with active hepatitis in the past could still accumulate more liver injury with increased risk of HCC,” they explained.

Second, those with positive anti-HBc often present with detectable HBV DNA or covalently closed circular DNA in the liver, even with negative serum HBV DNA. In addition, HBV DNA integration into the host genome occurs frequently in chronic HBV patients, persisting even after HB surface antigen seroclearance, according to the researchers. [Hepatology 2011;54:829-836]

“HBV DNA integration is one of the recognized mechanisms for HCC development,” they added. [J Hepatol 2016;64:S84-101]

Of note, patients with positive anti-HBc had lower body weight and body mass index, higher high-density lipoprotein cholesterol, and a trend toward lower triglycerides, suggesting that the metabolic factors were the main drivers of liver disease in those with negative anti-HBc, while both metabolic factors and previous HBV infection were responsible for liver injury in patients with positive anti-HBc, according to the researchers.

Additionally, “[b]ecause NAFLD-related HCC may develop in noncirrhotic patients, future studies should define the role of anti-HBc in selecting noncirrhotic patients with NAFLD for HCC surveillance,” they noted. [Clin Gastroenterol Hepatol 2011;9:428-433; Clin Gastroenterol Hepatol 2016;14:124-131.e1]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.